[8-K] Advanced Biomed Inc. Reports Material Event

Rhea-AI Filing Summary

Meridian Corporation (NASDAQ: MRBK) filed a Form 8-K dated July 24, 2025 covering two items:

• Item 2.02 – Q2 2025 results furnished: the company supplied a press release (Exhibit 99.1) that contains second-quarter 2025 financial performance figures. Those numbers are not reproduced in the 8-K and are treated as “furnished,” not “filed,” reducing related Exchange Act liability.
• Item 8.01 – Dividend declaration: the Board approved a quarterly cash dividend of $0.125 per common share, payable August 18, 2025 to shareholders of record on August 11, 2025.

No other material events, transactions, or financial statement adjustments were reported. The disclosure signals continued capital return via dividends and timely communication of quarterly results.

Positive

• Quarterly dividend of $0.125 per share declared, reaffirming consistent capital return policy.

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine 8-K; dividend maintained at $0.125 and Q2 results furnished, but no numbers shown—market impact likely limited.

The filing is largely procedural. Management reiterated its quarterly dividend, implying ongoing cash-flow stability. Because the actual Q2 metrics are only in the attached press release, investors must review Exhibit 99.1 to assess profitability, NIM trends, and credit quality. Absent those figures, the 8-K neither upgrades guidance nor announces material events. Thus, while dividend continuity is mildly supportive for income-oriented holders, valuation drivers remain unchanged until the detailed release is analyzed.

Dividend Specialist

TL;DR: Board confirms regular cash payout; rate steady at $0.125—no signal of acceleration or cut.

The $0.125 per-share distribution matches recent quarters, indicating management’s confidence in core earnings and capital ratios. Payout timing (record date 11-Aug, pay date 18-Aug) follows historical cadence. Because there is no increase, the action is neutral rather than overtly bullish, yet the absence of a cut amid uncertain macro conditions supports perceptions of balance-sheet resilience.

false 00000 0001941029 TW 0001941029 2025-07-18 2025-07-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

July 18, 2025

Date of Report (Date of earliest event reported)

Advanced Biomed Inc.

(Exact name of Company as specified in its charter)

Nevada		001-42548		87-2177170
(State or other jurisdiction		(Commission File Number)		(IRS Employer
of Incorporation)				Identification Number)

No. 689-85 Xiaodong Road, Yongkang District

Tainan City, Taiwan

(Address of principal executive offices)

886-6-3121716

(Registrant’s telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		ADVB		The Nasdaq Stock Market LLC

1

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On July 18, 2025, Advanced Biomed Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 32 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).

The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the Nasdaq Capital Market under the symbol “ADVB.”

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a compliance period of 180 calendar days, or until January 14, 2026 (the “Compliance Period”), to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of ten consecutive business days during the Compliance Period.

If the Company does not regain compliance by the end of the Compliance Period, the Company may be eligible for an additional 180 calendar day compliance period, provided that the Company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market (except for the bid price requirement), and provides written notice to Nasdaq of its intent to cure the deficiency during the second compliance period, including, if necessary, by effecting a reverse stock split.

The Company intends to monitor the closing bid price of its common stock and will consider all available options to regain compliance with the Minimum Bid Price Requirement within the compliance period.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements, including those related to the Company’s intent to regain compliance with Nasdaq’s continued listing requirements. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those stated or implied. These risks are detailed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Advanced Biomed Inc.
Date: July 24, 2025	By:	/s/ Yi Lu
		Yi Lu
		Chief Executive Officer

2

FAQ

What dividend did Meridian Corporation (MRBK) declare on July 24, 2025?

The Board approved a $0.125 cash dividend per common share.

When will MRBK shareholders receive the Q3 2025 dividend?

The dividend is payable on August 18, 2025 to shareholders of record as of August 11, 2025.

Does the 8-K include Meridian's Q2 2025 earnings numbers?

No. Financial figures are contained in the press release (Ex. 99.1), which is furnished but not reproduced in the form.

Why is the information marked as "furnished" rather than "filed"?

Marking it "furnished" limits Exchange Act liability, a common practice for earnings releases under Item 2.02.

Were any other material events disclosed in this 8-K?

No additional acquisitions, leadership changes, or financial statement revisions were reported.